Analysis and use of PAR 1 polymorphisms for the risk estimation of cardiovascular diseases

Details for Australian Patent Application No. 2004232459 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Kozian, Detlef; Siegler, Karl-Ernst; Ricard, Sylvain; Mace, Sandrine; Czech, Joerg; Deleuze, Jean-Francois

Agent Watermark

Pub. Number AU-B-2004232459

PCT Pub. Number WO2004/094470

Priority 103 18 496.1 24.04.03 DE

Filing date 16 April 2004

Wipo publication date 4 November 2004

Acceptance publication date 11 November 2010

International Classifications

C07K 14/72 (2006.01) Peptides having more than 20 amino acids

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

10 November 2005 PCT application entered the National Phase

  PCT publication WO2004/094470 Priority application(s): WO2004/094470

22 December 2005 Assignment before Grant

  Aventis Pharma Deutschland GmbH The application has been assigned to Sanofi-Aventis Deutschland GmbH Assignments before Grant, Section 113

11 November 2010 Application Accepted

  Published as AU-B-2004232459

10 March 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004232462-8$g(b)-vinyl-11$g(b)-($g(v)-substituted) alkyl-estra-1,3,5(10)-trienes

2004232456-Triazaand tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals